高危前列腺癌男性接受外照射放疗时雄激素剥夺治疗使用不足
该回顾性人群研究基于2008至2011年SEER-Medicare链接数据库,纳入961例接受根治性外照射放疗的Gleason分级分组4-5前列腺癌患者,分析雄激素剥夺治疗(ADT)使用情况。结果显示225例(23.4%)未接受ADT,仅126例(13.1%)接受≥24个月ADT,非西班牙裔白人相比,非洲裔美国男性接受1-6个月ADT versus 未接受ADT的比值比为0.519(95%CI 0.384-0.700)。
要点
- 961例接受根治性外照射放疗的GG 4-5前列腺癌患者中,225例(23.4%)未接受ADT。
- 仅126例(13.1%)接受≥24个月ADT,近90%患者ADT疗程不足24个月。
- 非洲裔美国男性接受1-6个月ADT versus 未接受ADT的比值比为0.519(95%CI 0.384-0.700)。
核心结论
- 长期ADT使用不足,近90%的GG 4-5前列腺癌患者接受<24个月伴随ADT。
- 非洲裔美国男性相比非西班牙裔白人男性更不可能接受ADT。
研究设计与样本
- 基于2008至2011年完整SEER-Medicare链接数据库的回顾性人群研究。
- 纳入961例接受根治性外照射放疗的GG 4-5前列腺癌非西班牙裔白人和非洲裔美国男性,伴或不伴ADT。
主要发现
- 961例接受根治性外照射放疗的患者中,225例(23.4%)未接受ADT,297例(30.9%)接受1-6个月ADT,313例(32.6%)接受7-23个月ADT,126例(13.1%)接受≥24个月ADT。
- 经逆概率治疗加权平衡其他协变量后,多分类逻辑回归显示非洲裔美国男性接受1-6个月ADT versus 未接受ADT的比值比为0.519(95%CI 0.384-0.700),仍显著低于非西班牙裔白人男性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple randomized trials have shown a survival benefit to long durations of androgen deprivation therapy (ADT) in patients with Gleason grade group (GG) 4-5 (ie, Gleason score 8-10) prostate cancer (PCa) undergoing definitive external beam radiotherapy (EBRT). We conducted a population-based retrospective study utilizing the complete Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database from 2008 to 2011, extracting PCa patients of non-Hispanic white (NHW) and African-American (AA) race diagnosed with GG 4-5PCa who received EBRT with or without concomitant ADT. Of 961 patients receiving definitive EBRT, 225 (23.4%) received no ADT, 297 (30.9%) received 1-6mo of ADT, 313 (32.6) received 7-23mo of ADT, and 126 (13.1%) received ≥24mo of ADT. On multinomial logistic regression after inverse probability treatment weighting to balance for differences in other covariates, AA men still had significantly lower odds of receiving 1-6mo of ADT versus no ADT compared with NHW men (odds ratios 0.519 [95% confidence interval, 0.384-0.700]). In conclusion, long-duration ADT is underutilized, with nearly 90% of patients with GG 4-5PCa receiving <24mo of concomitant ADT, and AA men are less likely to receive ADT than NHW men. PATIENT SUMMARY: In this report, we examined the utilization of concomitant androgen deprivation therapy (ADT) among men with high-grade prostate cancer undergoing definitive external beam radiotherapy. We found that long-duration ADT was underutilized overall; moreover, African-American men were less likely to receive concomitant ADT than non-Hispanic white men.
引用
- Wang C, Raldow AC, Nickols NG, et al. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31411981. doi:10.1016/j.euo.2019.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。